Ratings Hansa Biopharma AB BOERSE MUENCHEN

Equities

24H

SE0002148817

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:58 2024-05-28 pm EDT			5-day change	1st Jan Change
3.686 ^EUR	+6.66%		+3.60%	+41.76%

May. 21	Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting	CI
Apr. 18	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
HANSA BIOPHARMA AB	+41.76%	238M	-
MODERNA, INC.	+54.05%	63.85B	B-
IQVIA HOLDINGS INC.	-2.02%	41.83B	B
LONZA GROUP AG	+40.01%	40.47B	A
CELLTRION, INC.	-10.22%	27.17B	C
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B	B
BIO-TECHNE CORPORATION	+2.89%	12.73B	B+
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B	B+
MEDPACE HOLDINGS, INC.	+27.49%	12.07B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes